noom glp 1 companion program Doximity Noom Unveils Two New Enterprise

One common pattern involves dramatic week one and two gains, a frustrating week three to four plateau, then resumed progress in weeks five and six

For example, the U.S

Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minaker KL, Miles JM, Rubenstein AH, Vandepol CJ

van der Put, N

Reviews published in 2024 and 2025 also note growing interest in GLP-1 medications across rheumatology, especially for inflammatory arthritis and psoriasis

Cardiovascular outcome trials for liraglutide, semaglutide, and dulaglutide demonstrated modest blood pressure reductions alongside reduced major adverse cardiovascular events